DLA Piper advised Iovance Biotherapeutics in the deal. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced its definitive agreement with Clinigen Limited to acquire Proleukin® (aldesleukin), an interleukin-2…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Laura Testa
…
This content is for Standard 1 Year members only. LoginJoin Now